How Safe Is At-Home Ketamine Therapy? The Real Standards

Professional Oversight Requirements

Healthcare providers implementing at-home ketamine therapy must maintain rigorous supervision standards to ensure patient safety and treatment efficacy. The at-home model trades the controlled clinic environment for patient convenience and cost reduction, but it does not trade away the physician's duty of care. The supervision standards below reflect current best practices and the expectations of state medical boards for telehealth-delivered controlled substance therapy.

Physician Qualifications

The question of who is qualified to supervise at-home ketamine therapy is where the field most often encounters honest disagreement. At-home supervision is not a lesser form of ketamine medicine than clinic-based administration; it is, if anything, a more demanding one, because the physician is making safety decisions on incomplete sensory information and depending on a trained companion and a patient self-report to catch the events that a nurse in the room would simply observe. The credentials below are the floor, not the ceiling.

Required Credentials and Training

The supervising physician must hold:

• An active, unrestricted medical license in the state where the patient is physically located at the time of each session
• A valid DEA registration (or state equivalent) authorizing Schedule III controlled substance prescribing
• Completed training in ketamine pharmacology, dosing, and emergency management meeting or exceeding the minimum 68 hours outlined in ASKP3 and equivalent professional guidelines (see our Training Requirements guide)
• Current BLS certification at minimum; ACLS preferred for clinic-based providers
• Telemedicine competency training as required by the state medical board

Scope of Supervision

The prescribing physician is responsible for:

• Initial psychiatric evaluation and confirmation of treatment indication
• Patient selection, including contraindication screening and medical clearance
• Dosing decisions, titration, and route selection
• Real-time or near-real-time monitoring during sessions
• Clinical response evaluation (validated rating scales at each visit)
• Adverse event management and documentation
• Treatment plan modification, including discontinuation criteria
• Coordination with the patient's other healthcare providers

A physician cannot delegate the initial evaluation, dosing decisions, or the decision to initiate or discontinue treatment to mid-level providers. Session monitoring may be performed by a licensed nurse practitioner or physician assistant practicing under the physician's supervision, consistent with state scope-of-practice laws.

Telemedicine Monitoring Standards

The monitoring protocol below looks rigorous on paper and, in practice, runs briskly once the patient and clinician have done a session or two together. The intervals are designed to catch the specific adverse events that actually occur, not to create continuous observation for its own sake. What matters is not the number of check-ins but that each one is substantive: a clinician who is actually present, asking real questions, and documenting what they hear.

Synchronous Monitoring Protocol

At-home ketamine sessions must include real-time telemedicine contact with a clinician during at minimum the following intervals:

Pre-session check-in (5–10 minutes before dosing):

• Confirm the treatment companion is present and oriented to their role
• Assess patient's current mental status (PHQ-9 quick screen, suicidal ideation assessment)
• Review any interval changes in medications, health status, or substance use
• Confirm vital signs (BP, HR via home cuff; must be within acceptable range before dosing authorization)
• Confirm environment safety: patient in a comfortable, safe location; no driving planned for 12+ hours; sharp objects and fall hazards secured

Dosing authorization:

• The clinician verbally authorizes the patient to take the prescribed dose
• Patient self-administers the sublingual tablet under observation (holds sublingually for 10–15 minutes)
• Clinician documents dose, time, and administration compliance

Mid-session monitoring (30–45 minutes post-dose):

• Assess dissociative state: is the patient distressed, or is the experience proceeding without complications?
• Vital signs: patient or treatment companion reports BP and HR
• Escalation assessment: any signs of hypertensive crisis, respiratory distress, severe agitation, or medical emergency
• Brief verbal check-in (patients in the dissociative window may have difficulty with sustained conversation; a simple "are you okay?" with a nod or verbal affirmation is sufficient)

Post-session evaluation (60–90 minutes post-dose):

• Assess return to baseline orientation (alertness, conversational coherence, ambulatory stability)
• Vital signs: confirm BP/HR returning to baseline range
• Screen for residual nausea, dizziness, or distress
• Document session outcome (adverse events, subjective report, clinical impression)
• Reinforce post-session restrictions (no driving, no heavy machinery, no major decisions for 12 hours)
• Schedule next session or discuss treatment plan changes

Asynchronous Monitoring Supplements

Between sessions, the following asynchronous touchpoints strengthen supervision:

• 24-hour post-session check-in (text, secure message, or brief call): assess for delayed adverse effects, mood changes, integration observations
• Weekly mood tracking via PHQ-9 or equivalent validated instrument submitted electronically between sessions
• On-demand clinician access: patients must have a direct line (phone or secure messaging) to their prescribing physician or covering clinician during business hours, and a clear after-hours emergency protocol

Treatment Companion Requirements

The treatment companion is the single most important safety mechanism in the at-home model. Without them the entire supervision framework collapses; no amount of rigorous telemedicine contact compensates for the absence of a trained human being in the room if something unexpected occurs. The companion briefing is not a formality; it is the operational equivalent of having a nurse standing by during a clinic session.

Who Qualifies

• Any responsible adult (18+) who is physically present in the same location as the patient during the session
• Must be sober (no alcohol or impairing substances during the session)
• Must be capable of calling emergency services and providing basic assistance (guiding the patient to a safe position if disoriented, bringing water, communicating with the telemedicine clinician)
• Must be willing to remain present for the full session duration (typically 2 hours from dosing to clearance)

Who Does NOT Qualify

• Minors
• Individuals who are themselves receiving ketamine or any impairing substance
• Individuals with active restraining orders or domestic violence history involving the patient
• Individuals who are not physically present (a phone-only companion does not meet the standard)

Companion Briefing

Before the first session, the treatment companion must receive orientation from the clinical team covering:

• Expected effects of ketamine (what normal dissociation looks like vs. signs of distress)
• When and how to contact the monitoring clinician during a session
• When to call 911 (unresponsiveness, seizure activity, respiratory difficulty, chest pain)
• What NOT to do (do not try to "wake" the patient from a dissociative state; do not leave the patient unattended near stairs, water, or other fall hazards)
• Post-session care: ensure the patient does not drive, operate machinery, or make significant decisions for 12 hours

Emergency Escalation Protocols

Most at-home ketamine sessions require no escalation at all. A substantial minority produce Level 1 events that are handled routinely. The Level 2 and Level 3 scenarios are uncommon but real, and the clinicians who have them memorized (who can call the right cascade without having to look it up) respond in the window where response matters. The tiered framework below is designed to be drilled, not looked up mid-event.

Tiered Response Framework

Level 1: Manageable in session (clinician-directed)

• Mild to moderate nausea → instruct ondansetron 4 mg or positional change
• Anxiety during dissociation → verbal reassurance, guided breathing
• Blood pressure mildly elevated (systolic 160–180) → monitor, position supine, recheck in 15 minutes

Level 2: Session termination, remote clinical management

• Blood pressure persistently >180/110 despite 15 minutes of rest → consider sublingual antihypertensive if available; document and arrange urgent follow-up
• Severe panic or agitation unresponsive to verbal de-escalation → consider rescue benzodiazepine (if pre-authorized in the treatment plan)
• Prolonged dissociation (>90 minutes without returning to conversational baseline) → continue monitoring, extend session, and document

Level 3: Emergency services activation

• Unresponsiveness to verbal or tactile stimulation
• Observed seizure activity
• Respiratory distress (audible stridor, cyanosis, or apnea reported by companion)
• Chest pain or symptoms consistent with acute coronary syndrome
• The companion is unable to reach the monitoring clinician AND the patient's status is uncertain

The clinician must instruct the treatment companion to call 911. The clinician remains on the telemedicine connection until EMS arrives and provides a verbal handoff including: patient name, medication administered, dose, time, and current presentation.

Documentation Requirements

In an at-home model, the medical record is the primary external evidence that supervision occurred. A well-kept session note reconstructs, for anyone reviewing it later, what the physician knew, when they knew it, and why they made the decisions they did. Inadequate documentation doesn't only create liability exposure; it prevents the clinical learning that consistent records enable.

Per-Session Record

Each session note in the medical record must include:

• Date, time of session start and end
• Pre-session PHQ-9 (or equivalent) score
• Pre-session and mid-session vital signs
• Medication, dose, route, and hold time
• Dosing authorization confirmation (documented verbal order or protocol-based authorization)
• Treatment companion identity and presence confirmed
• Dissociative effects (onset, peak, resolution: subjective and observed)
• Adverse events (categorized by severity and relationship to treatment)
• Post-session assessment: return to baseline, ambulatory status, residual symptoms
• Clinical impression: response trajectory, plan for next session, any dose or frequency adjustment
• Patient instructions provided (driving restriction, when to call, next appointment)

Aggregate Tracking

The practice must maintain running records of:

• Treatment outcome trajectory per patient (PHQ-9 trend over time)
• Cumulative adverse event log per patient
• Program-level response and remission rates
• Emergency escalation events and outcomes
• Treatment companion compliance (any sessions where companion was absent or inadequate)

These aggregate metrics serve quality improvement, regulatory compliance, and potential payer negotiation purposes.

Regulatory Compliance for At-Home Programs

The regulatory landscape for telemedicine-delivered controlled substances is evolving quickly, and the rules that applied when a practice launched may not be the rules that apply eighteen months later. State medical boards, the DEA, and commercial payers are each setting their own expectations; a compliance program that tracks only one of those sources will eventually be caught short by changes in another. Quarterly legal review is not excessive for this part of the practice.

DEA and State Controlled Substance Requirements

• The prescribing physician must hold a DEA registration valid for the address from which telemedicine consultations are conducted
• Prescriptions must comply with state-specific telemedicine prescribing rules for Schedule III substances (some states require an initial in-person or synchronous video visit before controlled substance prescribing; some require periodic in-person visits during ongoing treatment)
• PDMP must be queried before initial prescription and at minimum every 90 days during ongoing treatment
• Prescription quantities should be limited to the number of sessions until the next clinical review (typically 2–4 week supply), not bulk dispensed

HIPAA and Telemedicine Platform Requirements

• All monitoring sessions must be conducted on a HIPAA-compliant telemedicine platform with BAA in place
• Session recordings (if made) must be stored per HIPAA retention requirements and cannot be used for marketing or research without separate IRB-approved consent
• Patient data transmitted during sessions (vital signs, clinical notes) must be encrypted in transit and at rest

Malpractice and Liability Considerations

• Physicians should carry malpractice insurance that explicitly covers telemedicine-delivered controlled substance prescribing and off-label use
• Many malpractice carriers require notification when adding ketamine therapy to a practice's service line; failure to disclose may void coverage
• Documentation of the treatment companion briefing and confirmation of their presence at each session is a critical liability protection: in a malpractice case, the question "was someone there with the patient?" will be asked

Quality Metrics for Program Evaluation

The metrics below are the minimum data a responsible program reviews on a recurring cycle. A practice that hits these targets has genuine evidence of clinical quality; a practice that tracks them and misses them has the information it needs to improve. The third category, a practice that does not track them at all, is operating on faith — which is not a standard of care the field should accept.

Programs should target and track:

Metric	Target	Review Frequency
PHQ-9 response rate (≥50% reduction)	>50%	Quarterly
Treatment retention at 3 months	>70%	Quarterly
Level 2+ escalation events	<5% of sessions	Monthly
Level 3 (EMS activation) events	<0.5% of sessions	Per occurrence
Treatment companion present at all sessions	100%	Per session
PDMP queried within 90-day window	100%	Monthly audit
Session documentation completed within 24 hours	100%	Monthly audit

Deviations from these targets should trigger a structured review by the clinical lead, with corrective action documented and implemented.

Frequently Asked Questions

What separates a legitimate at-home ketamine program from a substandard one?

Look for: physician with an active state medical license (verifiable through state board), DEA registration, formal psychiatric assessment training, ACLS certification or equivalent, and ongoing CME in ketamine therapy specifically. Operational signals: real medical and psychiatric evaluation by the prescribing physician (not an asynchronous form), blood-pressure cutoffs and screening protocols, required sober support person, physician reachable during sessions, clear escalation paths. Red flags: no doctor visit required, no eligibility screen, foreign pharmacies, "guaranteed approval," or any program that won't tell you who specifically will be your physician.

What blood pressure or cardiovascular limits apply to at-home ketamine?

Typical disqualifying thresholds: blood pressure consistently >160/100 without optimization, history of myocardial infarction within recent years, untreated coronary artery disease, severe heart failure, recent stroke, or untreated arrhythmias. Patients with controlled hypertension on medication can usually be approved with appropriate monitoring. Pre-session BP is checked; sessions are deferred if BP is markedly elevated that day. The threshold isn't arbitrary; ketamine produces a transient 15-25% systolic rise that's a non-event in healthy patients but problematic with significant cardiovascular comorbidity.

Is the supervising physician actually available during my session?

In a legitimate program, yes. The prescribing physician (or a covering physician of equivalent training) should be reachable by phone for the duration of every session, not "available business hours" but immediately reachable for the full 90-minute dosing window. The support person has the physician's direct contact for any concerns. This is a non-negotiable element of the at-home model; programs that delegate session coverage to chatbots, intake staff, or have no physician backup during sessions are operating outside the standard of care.

When should the support person call 911 instead of the physician?

Call 911 immediately for: difficulty breathing or signs of airway obstruction, severe chest pain, signs of stroke (sudden weakness, slurred speech, severe headache), seizure activity, loss of consciousness that doesn't resolve, or persistent severe distress that the support person cannot manage. Call the physician for: nausea, vomiting that's manageable, mild blood-pressure variability, anxiety or distress that's responding to grounding, or anything that feels off but doesn't fit the 911 list. The escalation rule: if there's any uncertainty between the two, call 911 first and the physician second; don't delay emergency care to consult.

Wondering whether at-home ketamine therapy is right for you?

Tovani Health is a physician-led at-home ketamine therapy practice serving Florida and New Jersey. We follow the supervision standards above on every session: a licensed physician evaluates eligibility, sets dosing, and is reachable for the full 90-minute window of every dose. The fastest way to know if you're a candidate is our free 5-minute eligibility assessment.

Check your eligibility →

Questions before you submit? Call 561-468-6981 to speak with our team.

Benjamin Soffer, DO — Tovani Health

---

Related professional reading: clinical protocols and patient selection, clinical supervision protocols, emergency management protocols, practice management.

These supervision standards are published by Tovani Health as professional guidance for healthcare providers implementing at-home ketamine therapy programs. They do not create a standard of care and should be adapted to individual practice contexts and state-specific regulatory requirements.